Published in Cancer Weekly, November 17th, 1997
This protein, referred to as VE-cadherin-2, is believed to enable the formation of a capillary blood vessel network in solid tumors, an essential step in the uncontrolled growth of malignancies. ImClone Systems is developing antagonists to VE-cadherin-2 to inhibit tumor vascularization.
In connection with its acquisition of exclusive relevant patent applications, the company initiated a collaboration with Mario Negri Institute (Milan, Italy) to conduct...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.